SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

BRITO, Vinicius Nahime; LATRONICO, Ana Claudia; ARNHOLD, Ivo J. P.  and  MENDONCA, Berenice Bilharinho. Update on the etiology, diagnosis and therapeutic management of sexual precocity. Arq Bras Endocrinol Metab [online]. 2008, vol.52, n.1, pp. 18-31. ISSN 0004-2730.  http://dx.doi.org/10.1590/S0004-27302008000100005.

    1. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol (Oxf). 2002; 56:129-48. [ Links ]

    2. Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997; 99:505-12. [ Links ]

    3. Midyett LK, Moore WV, Jacobson JD. Are pubertal changes in girls before age 8 benign? Pediatrics. 2003; 111:47-51. [ Links ]

    4. Crofton PM, Evans NE, Wardhaugh B, Groome NP, Kelnar CJ. Evidence for increased ovarian follicular activity in girls with premature thelarche. Clin Endocrinol. 2005; 62:205-9. [ Links ]

    5. De Vries L, Horev G, Schwartz M, Phillip M. Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol. 2006; 154:891-8. [ Links ]

    6. Pasquino AM, Pucarelli I, Passeri F, Segni M, Mancini MA, Municchi G. Progression of premature thelarche to central precocious puberty. J Pediatr. 1995; 126:11-4. [ Links ]

    7. Neville KA, Walker JL. Precocious pubarche is associated with SGA, prematurity, weight gain, and obesity. Arch Dis Child. 2005; 90: 258-261. [ Links ]

    8. Ibáñez L, Potau N, Marcos MV, Zegher F. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. J Clin Endocrinol Metab. 1999; 84:4739-41. [ Links ]

    9. Ong K, Potau N, Petry CJ, Jones R, Ness AR, Honour JW, et al. Opposing Influences of Prenatal and Postnatal Weight Gain on Adrenarche in Normal Boys and Girls. J Clin Endocrinol Metab. 2004; 89:2647-51. [ Links ]

    10. Banerjee I, Clayton P. The genetic basis for the timing of human puberty. J Neuroendocrinol. 2007; 19(11):831-8. [ Links ]

    11. Teles M, Bianco SC, Brito VN, Trarbach E, Seminara SB, Arnhold IJP, et al. An activating mutation in GPR54 causes gonadotropin-dependent precocious puberty. Proceedings of the 88th Annual Meeting of the Endocrine Society. Boston MA: Endocrine Society, 2006: OR34-3. [ Links ]

    12. Silveira LG, Santos MAG; Brito VN, Arnhold IJP, Mendonca, BB, Latronico AC. In vitro study of a KiSS1 gene missense mutation identified in a boy with idiopathic gonadotropin-dependent precocious puberty. Proceedings of the 89th Annual Meeting of the Endocrine Society.Toronto: Endocrine Society. 2007; P2-459. [ Links ]

    13. Brito VN, Latronico AC, Arnhold IJ, Lo LS, Domenice S, Albano MC, et al. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. Arch Dis Child. 1999; 80:231-4. [ Links ]

    14. Jung H, Carmel P, Schwartz MS, Witkin JW, Bentele KHP, Westphal M, et al. Some hypothalamic hamartomas contain transforming growth factor a, a puberty-inducing growth factor, but not luteinizing hormone-releasing hormone neurons. J Clin Endocrinol Metab. 1999; 84:4695-701. [ Links ]

    15. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44:291-303. [ Links ]

    16. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970; 45:13-23. [ Links ]

    17. Brito VN, Batista MC, Borges MF, Latronico AC, Kohek MBF, Thirone AC et al. Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab. 1999; 84:3539-44. [ Links ]

    18. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab. 2004; 89:4338-42. [ Links ]

    19. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics. 2002; 109:E30. [ Links ]

    20. Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of Basal and Gonadotropin-Releasing Hormone-Stimulated Gonadotropins by Immunochemiluminometric and Immunofluorometric Assays in Normal Children. J Clin Endocrinol Metab. 2007; 92: 1424-9. [ Links ]

    21. Neely EK, Hintz RL, Wilson DM, Lee PA, Gautier T, Argente J, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr. 1995; 127:40-6. [ Links ]

    22. Oerter KE, Uriarte MM, Rose SR, Barnes KM, Cutler Jr GB. Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab. 1991; 73:1235-40. [ Links ]

    23. Cavallo A, Richards GE, Busey S, Michaels SE. A simplified gonadotrophin-releasing hormone test for precocious puberty. Clin Endocrinol (Oxf). 1995; 42:641-6. [ Links ]

    24. Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, et al. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics. 1996; 97:517-9. [ Links ]

    25. Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. 2003; 24:668-93. [ Links ]

    26. Heger S, Sippell WG, Partsch CJ. Gonadotropin-releasing hormone analogue treatment for precocious puberty. Twenty years of experience. Endocr Dev. 2005; 8:94-125. [ Links ]

    27. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab. 2002; 87:4111-6. [ Links ]

    28. Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, et al. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf). 2002; 57(2):223-30 [ Links ]

    29. Brito VN, Monteiro KC, Mendonca BB, Latronico AC, Arnhold IJ. Uso trimestral de acetato de leuprolide (11,25 mg) no controle hormonal da puberdade precoce dependente de gonadotrofinas. IV COPEM - Congresso Paulista de Endocrinologia e Metabologia. Arq Bras Endocrinol Metab. 2001; 45: PO 07. [ Links ]

    30. Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics. 2005; 116(6):e798-802. [ Links ]

    31. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007; 92(5):1697-704. [ Links ]

    32. Tonini G, Marinoni S, Forleo V. Local reactions to luteinizing hormone releasing hormone analog therapy. J Pediatr. 1995;126:150-60. [ Links ]

    33. Palmert MR, Mansfield MJ, Crowley Jr. WF, Crigler Jr JF, Crawford JD, Boepple PA. Is Obesity an Outcome of Gonadotropin-Releasing Hormone Agonist Administration? Analysis of Growth and Body Composition in 110 Patients with Central Precocious Puberty. J Clin Endocrinol Metab. 1999; 84: 4480-8. [ Links ]

    34. Parker KL, Baens-Bailon RG, Lee PA. Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab. 1991; 73:50-2. [ Links ]

    35. Cook JS, Doty KL, Conn PM, Hansen JR. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty. J Clin Endocrinol Metab. 1992; 74:1206-9. [ Links ]

    36. Witchel SF, Baens-Bailon RG, Lee PA. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy. J Clin Endocrinol Metab. 1996; 81:1353-6. [ Links ]

    37. Lawson ML, Cohen N. A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab. 1999; 84:4536-40. [ Links ]

    38. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006; 91(5):1862-7. [ Links ]

    39. Lazar L, Pertzelan A, Weintob N, Philipp M, Kauli R. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and FH. J Clin Endocrinol Metab. 2001; 86(9):4127-32. [ Links ]

    40. Rizzo V, De Sanctis V, Corrias A, Fortini M, Galluzzi F, Bertelloni S, Guarneri MP, et al. Factors influencing final/near FH in 12 boys with central precocious puberty treated with gonadotropin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty. J Pediatr Endocrinol Metab. 2000: 13(1): 781-6. [ Links ]

    41. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: FH results. Horm Res. 2002; 58(1):1-7. [ Links ]

    42. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999; 84: 4583-90. [ Links ]

    43. Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab. 2003; 88(3):1096-101. [ Links ]

    44. Pasquino AM, Municchi G, Pucarelli I, Segni M, Mancini MA, Troiani S. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty. J Clin Endocrinol Metab. 1996; 81:948-51. [ Links ]

    45. Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab. 2003; 16:1005-10. [ Links ]

    46. Vottero A, Pedori S, Verna M, Pagano B, Cappa M, Loche S, et al. Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone. J Clin Endocrinol Metab. 2006; 91: 1284-7. [ Links ]

    47. Roth C. Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Expert Opin Investig Drugs. 2002; 11(9):1253-9. [ Links ]

    48. dAlva CB, Brito VN, Palhares HM, Carvalho FM, Arnhold IJ, Mendonca BB, et al. A single somatic activating Asp578His mutation of the luteinizing hormone receptor causes Leydig cell tumour in boys with gonadotropin-independent precocious puberty. Clin Endocrinol (Oxf). 2006; 65(3):408-10. [ Links ]

    49. Fragoso MC, Latronico AC, Carvalho FM, Zerbini MC, Marcondes JAM, Araujo LM, et al. Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab. 1998; 83:2074-8. [ Links ]

    50. Kotlar TJ, Young RH, Albanese C, Crowley WF, Scully RE, Jameson JL. A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. J Clin Endocrinol Metab. 1997; 82:1020-6. [ Links ]

    51. Batista MC, Kohek MB, Frazzatto ES, Fragoso CM, Mendonca BB, Latronico AC. Mutation analysis of the follicle-stimulating hormone receptor gene in girls with gonadotropin-independent precocious puberty resulting from autonomous cystic ovaries. Fertil Steril. 2000; 73:280-3. [ Links ]

    52. Anasti JN, Flack MR, Froehlich J, Nelson LM, Nisula BC. A potential novel mechanism for precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab. 1995; 80:276-9. [ Links ]

    53. Ryan GL, Feng X, dAlva CB, Zhang M, Van Voorhis BJ, Pinto EM, et al. Evaluating the Roles of Follicle-Stimulating Hormone Receptor Polymorphisms in Gonadal Hyperstimulation Associated with Severe Juvenile Primary Hypothyroidism J Clin Endocrinol Metab. 2007; 92: 2312-7. [ Links ]

    54. Kalantaridou SN, Chrousos GP. Clinical review 148: Monogenic disorders of puberty. J Clin Endocrinol Metab. 2002; 87:2481-94. [ Links ]

    55. Bachega TA, Billerbeck AE, Madureira G, Marcondes JAM, Longui CA, Leite MV, et al. Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1998; 83:4416-9. [ Links ]

    56. Marui S, Torrealba IM, Russell AJ, Latronico AC, Sutcliffe RG, Mendonca BB. A novel homozygous nonsense mutations E135* in the type II 3beta-hydroxysteroid dehydrogenase gene in a girl with salt-losing congenital adrenal hyperplasia. Mutations in brief no. 168. Online. Hum Mutat. 1998; 12:139. [ Links ]

    57. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991; 325:1688-95. [ Links ]

    58. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003; 88:4569-75. [ Links ]

    59. Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, Wu S, et al. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci U S A. 1995; 92:1906-10. [ Links ]

    60. Latronico AC, Shinozaki H, Guerra G Jr, Pereira MA, Maini SH, Baptista MT, et al. Gonadotropin-independent precocious puberty due to luteinizing hormone receptor mutations in Brazilian boys: a novel constitutively activating mutation in the first transmembrane helix. J Clin Endocrinol Metab. 2000; 85(12): 4799-805. [ Links ]

    61. Martin RM, Lin CJ, Nishi MY, Billerbeck AEC, Latronico AC, Russel DW, et al. Familial hyperestrogenism in both sexes: clinical, hormonal, and molecular studies of two siblings. J Clin Endocrinol Metab. 2003; 88:3027-34. [ Links ]

    62. Morishima A, Grumbach MM, Simpson ER, Fischer C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995; 80(12):3689-98. [ Links ]

    63. Mendonca BB, Leite MV, de Castro M, Tomoshige K, Elias LLK, Bachega TA, et al. Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene. J Clin Endocrinol Metab. 2002; 87(4):1805-9. [ Links ]

    64. Bertrand J, Loras S, Saez J, Forest M, Peretti E, Jeune M. Precocious puberty during chronic adrenal insufficiency. Another example of complex drag-effect endocrinopathy. Ann Pediatr. 1965; 12:772-7. [ Links ]

    65. Marilus R, Dickerman Z, Kaufman H, Versano I, Laron Z. Addisons disease associated with precocious sexual development in a boy. Acta Pediatr Scand. 1981; 70:587-9. [ Links ]

    66. Domenice S, Latronico AC, Brito VN, Arnhold IJP, Kok F, Mendonca BB. Adrenocorticotropin-dependent precocious puberty of testicular origin in a boy with X-linked adrenal hypoplasia congenita due to a novel mutation in the DAX1 gene. J Clin Endocrinol Metab. 2001; 86:4068-71. [ Links ]

    67. Soriano-Guillén L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. Adult Height after Ketoconazole Treatment in Patients with Familial Male-Limited Precocious Puberty J Clin Endocrinol Metab. 2005; 90: 147-151. [ Links ]

    68. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr. 2003; 143:60-6. [ Links ]

    69. Feuillan P, Merke D, Leschek EW, Cutler GB Jr. Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer. 1999; 6:303-6. [ Links ]

    70. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole Treatment of Precocious Puberty in Girls with the McCune-Albright Syndrome: A Pilot Study J Clin Endocrinol Metab. 2007; 92: 2100-6. [ Links ]

    71. DAlva CB, Latronico AC, Brito VN, Teles M, Arnhold IJ, Mendonca BB. Diagnosis and treatment of girls with gonadotropin-independent precocious puberty due to autonomous ovarian cysts. In: XVII Encontro da SLEP - Sociedade Latino-Americana de Endocrinologia Pediatrica. J Ped Endocrinol Metab. 2004; 17:1355. [ Links ]

    [ Links ]